Sanofi Genzyme steps in to fill gap left by New Zealand's failure to pay for rare disease drugs
PERTH, Australia – More patients with Pompe disease in New Zealand will now have access to Sanofi Genzyme's enzyme replacement therapy Myozyme (alglucosidase alfa), but not because the country's single payer will pay for the drug. Rather, Sanofi Genzyme, of Cambridge, Mass., part of Sanofi SA, has stepped in to provide the therapy for free to patients in New Zealand.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST